Preprint / Version 1

COVID-19: Implications for People with Chagas Disease

##article.authors##

  • Ezequiel Zaidel Sanatorio Güemes, Buenos Aires, Argentina and Pharmacology Department, School of Medicine, University of Buenos Aires, Argentina https://orcid.org/0000-0001-8349-7507
  • Colin Forsyth Drugs for Neglected Diseases initiative-Latin America, Rio de Janeiro, Brazil https://orcid.org/0000-0003-1481-8367
  • Gabriel Novick Swiss Medical Group, Buenos Aires, Argentina and Friedman School of Nutrition Science and Policy, Tufts University, Boston, USA https://orcid.org/0000-0001-5664-7522
  • Rachel Marcus Latin American Society of Chagas, Washington, DC, USA https://orcid.org/0000-0002-6229-8864
  • Antonio Luiz Ribeiro Internal Medicine Department, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil and Hospital das Clínicas, UFMG, Belo Horizonte, Brazil https://orcid.org/0000-0002-2740-0042
  • Maria Jesus Pinazo ISGlobal Hospital Clínic - University of Barcelona, Barcelona, Spain https://orcid.org/0000-0002-4237-1075
  • Carlos Morillo Libin Cardiovascular Institute, University of Calgary, Calgary, Canada https://orcid.org/0000-0002-8739-2099
  • Luis Eduardo Echeverria Department of Cardiology, Cardiovascular Foundation of Colombia, Floriblanca, Colombia
  • Maria Aparecida Shikanai-Yasuda Department of Infectious and Parasitic Diseases, School of Medicine, University of São Paulo, São Paulo, Brazil https://orcid.org/0000-0003-3864-041X
  • Pierre Buekens Tulane University School of Public Health and Tropical Medicine, New Orleans, USA https://orcid.org/0000-0002-4294-8559
  • Pablo Perel World Heart Federation, Geneva, Switzerland and Department of Non Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK https://orcid.org/0000-0002-2342-301X
  • Sheba Meymandi Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center, Sylmar, USA
  • Kate Ralston World Heart Federation, Geneva Switzerland
  • Fausto Pinto World Heart Federation, Geneva, Switzerland and Department of Cardiology, CCUL, Lisbon School of Medicine, Universidade de Lisboa, Portugal https://orcid.org/0000-0002-8034-4529
  • Sergio Sosa-Estani Drugs for Neglected Diseases initiative-Latin America, Rio de Janeiro, Brazil and Epidemiology and Public Health Research Center, (CIESP-CONICET), Buenos Aires, Argentina https://orcid.org/0000-0001-8701-5456

DOI:

https://doi.org/10.1590/SciELOPreprints.1144

Keywords:

Chagas disease, COVID-19, neglected tropical diseases (NTDs)

Abstract

As the global COVID-19 pandemic advances, it increasingly impacts the vulnerable populations who already bear a heavy burden of neglected tropical diseases. Chagas disease (CD), a neglected parasitic infection, is of particular concern because of its potential to cause cardiac, gastrointestinal, and other complications which could increase susceptibility to COVID-19. The over one million people worldwide with chronic Chagas cardiomyopathy require special consideration because of COVID-19’s potential impact on the heart, yet the pandemic also affects treatment provision to people with acute or chronic indeterminate CD. In this document, a follow-up to the WHF-IASC Roadmap on CD, we assess the implications of coinfection with SARS-CoV-2 and Trypanosoma cruzi, the etiological agent of CD. Based on the limited evidence available, we provide preliminary guidance for testing, treatment, and management of patients affected by both diseases, while highlighting emerging healthcare access challenges and future research needs.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Posted

2020-09-01

Section

Health Sciences